Anti-CD38 monoclonal antibodies continue to demonstrate promising results as new trea™ents for patients with multiple myeloma. Therapeutic anti-CD38 targets this molecule, highly expressed on the surface of multiple myeloma cells, hampering its detection by flow cytometry.

Cytognos has developed an anti-human CD38 multi-epitope reagent containing a mixture of antibodies that allows the identification by flow cytometry of CD38 molecule on plasma cells, even in patients under anti-CD38 therapy.

Comparative evaluation by flow cytometry of CD38-FITC monoclonal (dark grey dots)
and CD38-FITC multi-epitope (CYT-38F2; red dots) performance.
A) Bone marrow sample from untreated patient.
B) Patient treated with therapy 1.
C) Patient treated with therapy 2.